Abstracts tagged "high risk"

Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Hamayon Babary¹, Suraiya Afroz ¹, John Carter ¹, Yih Lin ¹, Marie O'Brien ², Marcos Maldonado ¹, Helen Bateman ¹, Gabriela Montes-Rivera ¹, Grace Berlin ², Dan Tseytlin ², Madeline MacDonald ³, Yasmin Ayoubi ⁴, Matthew Nguyen ⁴, Shalini Setty ⁴, Rahul Mhaskar ⁴ and Joanne Valeriano-Marcet ¹, ¹University of South Florida Division of Rheumatology, Tampa, FL, ²Lehigh Valley Health Network, Allentown, PA, ³University of South Florida, College of Medicine, Tampa, FL, ⁴University of South Florida College of Medicine, Tampa, FL
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…
Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 2674 • 2018 ACR/ARHP Annual Meeting
Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster
Ga Young Ahn¹, Jiyoung Lee², Eunji Ha³, Kwangwoo Kim³, Hyoungyoung Kim¹, Ji Soong Kim¹, Bora Nam¹, Juyeon Kang¹, Hyuk-Hee Kwon¹, So-Young Bang¹, Hye-Soon Lee¹ and Sang-Cheol Bae¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, Republic of (South), ³Biology, Kyung Hee University, Seoul, Korea, Republic of (South)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease with complex genetic background. Recently, subphenotype in SLE has influenced dialogue on discussing the genetic…
Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 3142 • 2016 ACR/ARHP Annual Meeting
Improving Counseling, Documentation and Adherence to Highly Effective Birth Control in Women on Teratogenic Medications at a Rural Medical Center: A Quality Improvement Initiative
Sonal Bhalla^1,2,3, John Mecchella^1,4 and Alicia Zbehlik^1,4,5, ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology/ Leardership Peventive Medicine Residency, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Instructor in Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Leadership Preventive Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Autoimmune and inflammatory diseases occur more often in women than in men, and often these women are of childbearing age. Many of the medications…
Abstract Number: 2513 • 2015 ACR/ARHP Annual Meeting
Contraception Use Amongst Women Ages 18-45 Taking Known Teratogenic Medications in an Academic Rheumatology Clinic
Rebecca Sadun, Nicholas Holdgate, Melissa Wells, Megan E. B. Clowse, Lisa Criscione-Schrieber, Stephen Balevic, Victoria Lackey, Samya Mohammad and Erica Peart, Rheumatology, Duke University Medical Center, Durham, NC

Background/Purpose: Patients with autoimmune diseases are often prescribed medications that are known to be teratogenic. Amongst women of child-bearing ages taking such medications, roughly half…
Abstract Number: 48 • 2014 ACR/ARHP Annual Meeting
Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study
Jonathan D. Adachi¹, David Goltzman², Ankita Modi³, Jackson Tang⁴, Chun-Po S. Fan⁴ and Jessica Weaver³, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²McGill University, Montreal, QC, Canada, ³Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, ⁴Asclepius Analytics, New York, NY
Background/Purpose Individuals with osteoporosis (OP) have an increased susceptibility to fractures. Prevention and treatment of postmenopausal OP is critical to decreasing the risk of non-traumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].